Supplemental Table S3 from Spatial Transcriptomic Analysis of Ovarian Cancer Precursors Reveals Reactivation of IGFBP2 during Pathogenesis

Supplemental Table S3 from Spatial Transcriptomic Analysis of Ovarian Cancer Precursors Reveals Reactivation of IGFBP2 during Pathogenesis

<p>Raw data provided by Nanostring bioinformatic team</p>

Сохранить в:

Библиографические подробности
Главный автор:	Yeh Wang (14964041) (author)
Другие авторы:	Peng Huang (14964044) (author), Brant G. Wang (14964047) (author), Tricia Murdock (14964050) (author), Leslie Cope (14964053) (author), Fang-Chi Hsu (14964056) (author), Tian-Li Wang (14964059) (author), Ie-Ming Shih (14964062) (author)
Опубликовано:	2025
Предметы:	Cancer Cancer Risk Factors Cancer Biology Tumor Biology Molecular and Cellular Biology Cancer Detection and Diagnosis Cancer Prevention Biomarkers Early detection biomarkers Cancer Interception Biomarkers and intervention Carcinogenesis Tumor initiation and promotion Epigenetics DNA methylation Gynecological Cancers Ovarian cancer Tumor Evolution
Метки:	Добавить метку Нет меток, Требуется 1-ая метка записи!

Схожие документы

Supplemental Table S4 from Spatial Transcriptomic Analysis of Ovarian Cancer Precursors Reveals Reactivation of IGFBP2 during Pathogenesis
по: Yeh Wang (14964041)
Опубликовано: (2025)

Supplementary Table S1 from Validation of the Clinical Use of GIScar, an Academic-developed Genomic Instability Score Predicting Sensitivity to Maintenance Olaparib for Ovarian Cancer
по: Raphaël Leman (17314506)
Опубликовано: (2025)

Supplementary Table S2 from Validation of the Clinical Use of GIScar, an Academic-developed Genomic Instability Score Predicting Sensitivity to Maintenance Olaparib for Ovarian Cancer
по: Raphaël Leman (17314506)
Опубликовано: (2025)

Supplementary Table S3 from Validation of the Clinical Use of GIScar, an Academic-developed Genomic Instability Score Predicting Sensitivity to Maintenance Olaparib for Ovarian Cancer
по: Raphaël Leman (17314506)
Опубликовано: (2025)

Supplementary Table S4 from Validation of the Clinical Use of GIScar, an Academic-developed Genomic Instability Score Predicting Sensitivity to Maintenance Olaparib for Ovarian Cancer
по: Raphaël Leman (17314506)
Опубликовано: (2025)

Supplementary Table S5 from Validation of the Clinical Use of GIScar, an Academic-developed Genomic Instability Score Predicting Sensitivity to Maintenance Olaparib for Ovarian Cancer
по: Raphaël Leman (17314506)
Опубликовано: (2025)

Supplementary Table S6 from Validation of the Clinical Use of GIScar, an Academic-developed Genomic Instability Score Predicting Sensitivity to Maintenance Olaparib for Ovarian Cancer
по: Raphaël Leman (17314506)
Опубликовано: (2025)

Figure 1 from Gene-Expression Profiling of Mucinous Ovarian Tumors and Comparison with Upper and Lower Gastrointestinal Tumors Identifies Markers Associated with Adverse Outcomes
по: Nicola S. Meagher (15048462)
Опубликовано: (2025)

Figure 2 from Gene-Expression Profiling of Mucinous Ovarian Tumors and Comparison with Upper and Lower Gastrointestinal Tumors Identifies Markers Associated with Adverse Outcomes
по: Nicola S. Meagher (15048462)
Опубликовано: (2025)

Figure 3 from Gene-Expression Profiling of Mucinous Ovarian Tumors and Comparison with Upper and Lower Gastrointestinal Tumors Identifies Markers Associated with Adverse Outcomes
по: Nicola S. Meagher (15048462)
Опубликовано: (2025)

Table 1 from Gene-Expression Profiling of Mucinous Ovarian Tumors and Comparison with Upper and Lower Gastrointestinal Tumors Identifies Markers Associated with Adverse Outcomes
по: Nicola S. Meagher (15048462)
Опубликовано: (2025)

Table 2 from Gene-Expression Profiling of Mucinous Ovarian Tumors and Comparison with Upper and Lower Gastrointestinal Tumors Identifies Markers Associated with Adverse Outcomes
по: Nicola S. Meagher (15048462)
Опубликовано: (2025)

Table 3 from Gene-Expression Profiling of Mucinous Ovarian Tumors and Comparison with Upper and Lower Gastrointestinal Tumors Identifies Markers Associated with Adverse Outcomes
по: Nicola S. Meagher (15048462)
Опубликовано: (2025)

Supplementary Tables S1-S11 from Gene-Expression Profiling of Mucinous Ovarian Tumors and Comparison with Upper and Lower Gastrointestinal Tumors Identifies Markers Associated with Adverse Outcomes
по: Nicola S. Meagher (15048462)
Опубликовано: (2025)

Supplemental Table S3 from Clonal Hematopoiesis in Young Women Treated for Breast Cancer
по: Christopher J. Gibson (15907642)
Опубликовано: (2025)

Supplemental Table S4 from Clonal Hematopoiesis in Young Women Treated for Breast Cancer
по: Christopher J. Gibson (15907642)
Опубликовано: (2025)

Supplementary Figure S7 from <i>NPY</i> Methylated ctDNA is a Promising Biomarker for Treatment Response Monitoring in Metastatic Colorectal Cancer
по: Katleen Janssens (15053356)
Опубликовано: (2025)

Supplementary Table S2 from Clinical Relevance of <i>BRCA1</i> Promoter Methylation Testing in Patients with Ovarian Cancer
по: Félix Blanc-Durand (15049400)
Опубликовано: (2025)

Supplementary Table 4: SpatialDecon derived immune cell counts from Spatially Resolved Transcriptomics Deconvolutes Prognostic Histological Subgroups in Patients with Colorectal Cancer and Synchronous Liver Metastases
по: Colin S. Wood (15293247)
Опубликовано: (2025)

Supplementary Table S3 from Circulating Exosomal PD-L1 at Initial Diagnosis Predicts Outcome and Survival of Patients with Osteosarcoma
по: Jun Wang (15051911)
Опубликовано: (2025)

Figure 1 from Spatially Resolved Transcriptomics Deconvolutes Prognostic Histological Subgroups in Patients with Colorectal Cancer and Synchronous Liver Metastases
по: Colin S. Wood (15293247)
Опубликовано: (2025)

Figure 2 from Spatially Resolved Transcriptomics Deconvolutes Prognostic Histological Subgroups in Patients with Colorectal Cancer and Synchronous Liver Metastases
по: Colin S. Wood (15293247)
Опубликовано: (2025)

Figure 3 from Spatially Resolved Transcriptomics Deconvolutes Prognostic Histological Subgroups in Patients with Colorectal Cancer and Synchronous Liver Metastases
по: Colin S. Wood (15293247)
Опубликовано: (2025)

Figure 4 from Spatially Resolved Transcriptomics Deconvolutes Prognostic Histological Subgroups in Patients with Colorectal Cancer and Synchronous Liver Metastases
по: Colin S. Wood (15293247)
Опубликовано: (2025)

Figure 5 from Spatially Resolved Transcriptomics Deconvolutes Prognostic Histological Subgroups in Patients with Colorectal Cancer and Synchronous Liver Metastases
по: Colin S. Wood (15293247)
Опубликовано: (2025)

Figure 6 from Spatially Resolved Transcriptomics Deconvolutes Prognostic Histological Subgroups in Patients with Colorectal Cancer and Synchronous Liver Metastases
по: Colin S. Wood (15293247)
Опубликовано: (2025)

Table 1 from Spatially Resolved Transcriptomics Deconvolutes Prognostic Histological Subgroups in Patients with Colorectal Cancer and Synchronous Liver Metastases
по: Colin S. Wood (15293247)
Опубликовано: (2025)

Supplementary Table S1 from Functional Homologous Recombination Assay on FFPE Specimens of Advanced High-Grade Serous Ovarian Cancer Predicts Clinical Outcomes
по: Sanna Pikkusaari (15055802)
Опубликовано: (2025)

Supplementary Table S2 from Functional Homologous Recombination Assay on FFPE Specimens of Advanced High-Grade Serous Ovarian Cancer Predicts Clinical Outcomes
по: Sanna Pikkusaari (15055802)
Опубликовано: (2025)

Supplementry Table 3: REACTOME Gene Set Enrichment Analysis results from Spatially Resolved Transcriptomics Deconvolutes Prognostic Histological Subgroups in Patients with Colorectal Cancer and Synchronous Liver Metastases
по: Colin S. Wood (15293247)
Опубликовано: (2025)

Figure 1 from Metabolomic Biomarkers in Blood Samples Identify Cancers in a Mixed Population of Patients with Nonspecific Symptoms
по: James R. Larkin (14936324)
Опубликовано: (2025)

Figure 2 from Metabolomic Biomarkers in Blood Samples Identify Cancers in a Mixed Population of Patients with Nonspecific Symptoms
по: James R. Larkin (14936324)
Опубликовано: (2025)

Figure 3 from Metabolomic Biomarkers in Blood Samples Identify Cancers in a Mixed Population of Patients with Nonspecific Symptoms
по: James R. Larkin (14936324)
Опубликовано: (2025)

Figure 4 from Metabolomic Biomarkers in Blood Samples Identify Cancers in a Mixed Population of Patients with Nonspecific Symptoms
по: James R. Larkin (14936324)
Опубликовано: (2025)

Figure 5 from Metabolomic Biomarkers in Blood Samples Identify Cancers in a Mixed Population of Patients with Nonspecific Symptoms
по: James R. Larkin (14936324)
Опубликовано: (2025)

Table 1 from Metabolomic Biomarkers in Blood Samples Identify Cancers in a Mixed Population of Patients with Nonspecific Symptoms
по: James R. Larkin (14936324)
Опубликовано: (2025)

Supplementary Table S1 from Additional Oncogenic Alterations in <i>RAS</i>-Driven Differentiated Thyroid Cancers Associate with Worse Clinicopathologic Outcomes
по: Athanasios Bikas (16006076)
Опубликовано: (2025)

Supplementary figures and tables FTS1 from Intraperitoneal Monocytes plus IFNs as a Novel Cellular Immunotherapy for Ovarian Cancer: Mechanistic Characterization and Results from a Phase I Clinical Trial
по: Daniel S. Green (15047598)
Опубликовано: (2025)

Supplementary file 3: Supplementary Tables. from circFNDC3B Accelerates Vasculature Formation and Metastasis in Oral Squamous Cell Carcinoma
по: Xiang Li (15386727)
Опубликовано: (2025)

Supplementary Video from Shortwave Infrared Imaging Enables High-Contrast Fluorescence-Guided Surgery in Neuroblastoma
по: Laura Privitera (16015972)
Опубликовано: (2025)

Cannot write session to /tmp/vufind_sessions/sess_qm7jboqbr4k282fi6otaj3oth1